Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCART22 in Relapsed/Refractory B-ALL (BALLI-01)
NCT04150497Phase 2Recruiting
- Sponsor
- Cellectis
- Start
- Oct 2019
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of UCART22 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Cellectis. Primary endpoints: Incidence of AE/SAE/DLT at 24 months and Occurrence of Dose Limiting Toxicities. Started Oct 2019; status: recruiting.
02
Drugs
UCART22
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04150497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04150497.